Tesamorelin Philippines 2026

Tesamorelin is a modified version of GHRH, growth hormone releasing hormone. It binds GHRH receptors in the pituitary and triggers the release of your own growth hormone in its natural pulsatile pattern, rather than delivering a flat synthetic dose the way injected HGH does. That pulsatile mechanism is the same reason people run the CJC-1295 no DAC and Ipamorelin stack. Tesamorelin is the version of that idea that made it all the way through regulatory review.

The US FDA approved it in 2010 under the brand name Egrifta, for a narrow indication: reducing visceral adipose tissue in HIV patients with lipodystrophy. Narrow indication, but the mechanism itself is not narrow. Elevated GH drives IGF-1 production in the liver, IGF-1 promotes lipolysis, and the resulting metabolic environment favors fat loss, with visceral stores responding most in the trial data.

Standard research dosing in the literature is 1mg daily subcutaneous for the first weeks, then 2mg daily through week 26 for maximum effect, with maintenance at 1 to 2mg daily after that. Once-daily injection, no complicated timing. The full compound dossier, including side effect and contraindication detail, lives on our tesamorelin compound page.

Most peptides in this category run on rodent studies and anecdote. Tesamorelin is the exception. Phase 3 clinical trials showed 15 to 26 percent reductions in visceral adipose tissue over 26 weeks. That is the fat wrapped around the liver, pancreas, and intestines, the metabolically active tissue linked to insulin resistance and chronic inflammation, not the subcutaneous fat you can pinch.

Two practical implications from the trial data. First, the timeline: waist measurements typically start moving by weeks 4 to 6, and the bulk of the reduction lands in the month 3 to 6 window. This is not a fast compound. Second, the reduction does not hold by itself: visceral fat generally returns after discontinuation, which is why the research pattern is either long maintenance or strict diet and training discipline built during the protocol.

Worth stating clearly: if your goal is total-body weight loss rather than visceral fat specifically, the GLP-1 class has far stronger data. Semaglutide posted 14.9 percent body weight reduction in STEP 1 and tirzepatide 22.5 percent in SURMOUNT-1. Our weight loss hub covers that entire category. Tesamorelin is for the leaner reader whose problem is specifically the midsection tissue that diet has not touched.

I am not going to print a peso figure here, because I have not verified a stable one. Tesamorelin quotes vary supplier to supplier more than any GH-axis compound I track, and a number published today would mislead someone in three months. What I can give you is the relative math, which has stayed consistent.

Tesamorelin runs roughly three times the cost of a CJC-1295 and Ipamorelin stack for a comparable growth hormone protocol. That multiple is the real decision point. If visceral fat is your specific research target and budget allows, tesamorelin has the strongest data. If your target is general body composition on a budget, the CJC and Ipamorelin stack is more versatile per peso, and pricing for it is far easier to verify locally.

Also budget for daily consumption. Tesamorelin doses at 1 to 2mg per day, every day. A once-daily 2mg protocol chews through vials faster than a 100mcg twice-daily secretagogue stack, which compounds the cost multiple further over a 26-week run. Get quotes in writing, per vial and per milligram, before committing to a full protocol.

The checklist for tesamorelin is the standard research-peptide one, applied more strictly because the compound is expensive and lower-volume. Third-party COA per batch, HPLC purity stated, cold-chain insulated packaging, and a written reshipment policy for customs detentions. A supplier who hesitates on any of those four is a supplier for someone else's money. Our supplier checklist is the maintained starting point.

Import lane: tesamorelin is not a scheduled substance under PH law, and personal-use research volumes generally clear when invoiced as research peptide. It is still an unregistered injectable, which means NAIA inspection can detain it. That risk is the argument for ordering from stock already inside the country when you can find it.

Stock is the story. My courier runs for tesamorelin have been the least predictable of any compound I track. Suppliers who reliably hold BPC-157 and Ipamorelin treat tesamorelin as an order-in item, and quoted lead times drift. If a protocol matters to you, secure the full run of vials before starting rather than buying month to month.

The stack question comes up constantly.Tesamorelin works through GHRH receptors, Ipamorelin through GHSR receptors, so combining them stimulates GH release through complementary pathways. That pairing is a legitimate research pattern, similar in shape to CJC and Ipamorelin but with tesamorelin's visceral fat data behind the GHRH half. It also doubles your sourcing problem, so plan supply accordingly.

Expect the water first. The consistent early report is fluid retention in the first weeks: puffy hands, tighter rings, sometimes wrist tingling. It normalizes as the protocol continues, and waist changes show up after it does. Anyone selling a two-week transformation on this compound has not read the trial timelines.